Australian Scientists awarded $2.5m in support of ground-breaking research into Alzheimer’s Disease and Leukaemia CSL 2017 Fellows

11-October-2016 — Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research that aims to help patients beat leukaemia and examine the origins of memory to better understand Alzheimer’s disease. More.

FDA Accepts CSL Behring’s BLA for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks Full Year Results Announced 2016

30-August-2016 — CSL today announced that the FDA has accepted for review CSL Behring’s BLA for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent HAE attacks. More.

Other recent news:

17-August-2016— Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 Sep 2016. Mr John Akehurst, has indicated his intention to retire at the conclusion of the Company’s AGM on 12 Oct 2016. More.
4-July-2016— CSL will be an inaugural partner of the new Australian Research Council Industrial Transformation Training Centre for Biopharmaceutical Innovation to be established at the University of Queensland. More.
10-June-2016 — Last night CSL Behring’s Australian facility was awarded ‘2016 Victorian Manufacturer of the Year’ at the Victorian Manufacturing Hall of Fame Awards. More.

© 2016 CSL Limited